Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
暂无分享,去创建一个
Ali Bashashati | Thomas Zeng | Stephen Yip | Yongjun Zhao | Richard A. Moore | Gavin Ha | Karey Shumansky | Kane Tse | Jamie Rosner | Andrew Roth | Sohrab P Shah | Jiarui Ding | Nataliya Melnyk | Janine Senz | Marco A Marra | David G Huntsman | Jessica N McAlpine | A. Bashashati | M. Marra | Yongjun Zhao | Thomas Zeng | S. Shah | Jiarui Ding | G. Ha | Jamie Rosner | D. Huntsman | Kane Tse | Andrew Roth | J. Senz | S. Kalloger | M. McConechy | M. Anglesio | Winnie Yang | J. McAlpine | L. Prentice | N. Melnyk | S. Yip | B. Gilks | K. Shumansky | A. Tone | M. Luk | Blake Gilks | Richard Moore | Winnie Yang | Steve Kalloger | Alicia Tone | Leah M Prentice | Melissa McConechy | Michael Anglesio | Margaret TY Luk | R. Moore | M. Mcconechy | Sohrab P. Shah | Nataliya Melnyk
[1] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[2] P. Spellman,et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.
[3] Joshy George,et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. , 2012, Cancer research.
[4] R. Buller,et al. Frequency of BRCA1 dysfunction in ovarian cancer. , 2002, Journal of the National Cancer Institute.
[5] I. Jacobs,et al. Genetic intra‐tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours , 2007, The Journal of pathology.
[6] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[7] A. Børresen-Dale,et al. The Life History of 21 Breast Cancers , 2012, Cell.
[8] Barry Rosen,et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.
[9] J. Thigpen. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations , 2009 .
[10] M. Piccart,et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.
[11] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[12] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[13] Yongjun Zhao,et al. Clonal evolution of high‐grade serous ovarian carcinoma from primary to recurrent disease , 2013, The Journal of pathology.
[14] Thomas J. Hardcastle,et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma , 2010, Oncogene.
[15] K. Schaefer,et al. Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.
[16] Lorena Losi,et al. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. , 2005, Carcinogenesis.
[17] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[18] R. Buller,et al. Inactivation of BRCA 1 and BRCA 2 in Ovarian Cancer , 2002 .
[19] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[20] H. Kitano. Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.
[21] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[22] M. Stratton,et al. The cancer genome , 2009, Nature.
[23] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[24] A. Schäffer,et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. , 1997, Cancer research.
[25] Sohrab P Shah,et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma , 2012, Modern Pathology.
[26] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[27] A. Tinker,et al. The role of the fallopian tube in ovarian cancer. , 2012, Clinical advances in hematology & oncology : H&O.
[28] Naveena Singh,et al. The clonal evolution of metastases from primary serous epithelial ovarian cancers , 2009, International journal of cancer.
[29] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[30] I. Shih,et al. Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous Carcinogenesis , 2010, The American journal of surgical pathology.
[31] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[32] J. Prat,et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. , 2004, Human pathology.
[33] Joe W Gray,et al. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. , 2003, Cancer cell.
[34] W. McCluggage,et al. WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma , 2004, Histopathology.
[35] R. Buller,et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. , 2002, Journal of the National Cancer Institute.
[36] N. Rosenfeld,et al. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.
[37] A. Bashashati,et al. DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer , 2012, Genome Biology.
[38] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[39] I. Shih,et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high‐grade serous carcinoma—evidence supporting the clonal relationship of the two lesions , 2012, The Journal of pathology.
[40] Shelley Tworoger,et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. , 2008, Gynecologic oncology.
[41] Marc K Halushka,et al. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. , 2010, Human pathology.
[42] Y. Lacasse,et al. From the authors , 2005, European Respiratory Journal.
[43] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.